281 related articles for article (PubMed ID: 27746226)
1. Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial.
Brooks WA; Zaman K; Lewis KD; Ortiz JR; Goswami D; Feser J; Sharmeen AT; Nahar K; Rahman M; Rahman MZ; Barin B; Yunus M; Fry AM; Bresee J; Azim T; Neuzil KM
Lancet Glob Health; 2016 Dec; 4(12):e946-e954. PubMed ID: 27746226
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial.
Victor JC; Lewis KD; Diallo A; Niang MN; Diarra B; Dia N; Ortiz JR; Widdowson MA; Feser J; Hoagland R; Emery SL; Lafond KE; Neuzil KM
Lancet Glob Health; 2016 Dec; 4(12):e955-e965. PubMed ID: 27746224
[TBL] [Abstract][Full Text] [Related]
3. Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh.
Ortiz JR; Goswami D; Lewis KD; Sharmeen AT; Ahmed M; Rahman M; Rahman MZ; Feser J; Neuzil KM; Brooks WA
Vaccine; 2015 Jun; 33(29):3415-21. PubMed ID: 25917680
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh.
Lewis KDC; Ortiz JR; Rahman MZ; Levine MZ; Rudenko L; Wright PF; Katz JM; Dally L; Rahman M; Isakova-Sivak I; Ilyushina NA; Matyushenko V; Fry AM; Lindstrom SE; Bresee JS; Brooks WA; Neuzil KM
Clin Infect Dis; 2019 Aug; 69(5):777-785. PubMed ID: 30481272
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of live attenuated and inactivated influenza vaccines among children in rural India: A 2-year, randomized, triple-blind, placebo-controlled trial.
Krishnan A; Dar L; Saha S; Narayan VV; Kumar R; Kumar R; Amarchand R; Dhakad S; Chokker R; Choudekar A; Gopal G; Choudhary A; Potdar V; Chadha M; Lafond KE; Lindstrom S; Widdowson MA; Jain S
PLoS Med; 2021 Apr; 18(4):e1003609. PubMed ID: 33914729
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
Bracco Neto H; Farhat CK; Tregnaghi MW; Madhi SA; Razmpour A; Palladino G; Small MG; Gruber WC; Forrest BD;
Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948
[TBL] [Abstract][Full Text] [Related]
8. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
King JC; Fast PE; Zangwill KM; Weinberg GA; Wolff M; Yan L; Newman F; Belshe RB; Kovacs A; Deville JG; Jelonek M;
Pediatr Infect Dis J; 2001 Dec; 20(12):1124-31. PubMed ID: 11740317
[TBL] [Abstract][Full Text] [Related]
9. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
Piedra PA; Gaglani MJ; Riggs M; Herschler G; Fewlass C; Watts M; Kozinetz C; Hessel C; Glezen WP
Pediatrics; 2005 Sep; 116(3):e397-407. PubMed ID: 16140685
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.
Nichol KL; Mendelman PM; Mallon KP; Jackson LA; Gorse GJ; Belshe RB; Glezen WP; Wittes J
JAMA; 1999 Jul; 282(2):137-44. PubMed ID: 10411194
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years.
Block SL; Toback SL; Yi T; Ambrose CS
Clin Ther; 2009 Oct; 31(10):2140-7. PubMed ID: 19922885
[TBL] [Abstract][Full Text] [Related]
12. Live attenuated influenza vaccine in children.
Ambrose CS; Walker RE; Connor EM
Semin Pediatr Infect Dis; 2006 Oct; 17(4):206-12. PubMed ID: 17055372
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.
Belshe RB; Ambrose CS; Yi T
Vaccine; 2008 Sep; 26 Suppl 4():D10-6. PubMed ID: 18611422
[TBL] [Abstract][Full Text] [Related]
14. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.
Tapia MD; Sow SO; Tamboura B; Tégueté I; Pasetti MF; Kodio M; Onwuchekwa U; Tennant SM; Blackwelder WC; Coulibaly F; Traoré A; Keita AM; Haidara FC; Diallo F; Doumbia M; Sanogo D; DeMatt E; Schluterman NH; Buchwald A; Kotloff KL; Chen WH; Orenstein EW; Orenstein LAV; Villanueva J; Bresee J; Treanor J; Levine MM
Lancet Infect Dis; 2016 Sep; 16(9):1026-1035. PubMed ID: 27261067
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.
Mallory RM; Malkin E; Ambrose CS; Bellamy T; Shi L; Yi T; Jones T; Kemble G; Dubovsky F
PLoS One; 2010 Oct; 5(10):e13755. PubMed ID: 21060780
[TBL] [Abstract][Full Text] [Related]
16. Influenza Among Young Children in Bangladesh: Clinical Characteristics and Outcomes From a Randomized Clinical Trial.
Rotrosen E; Zaman K; Feser J; Ortiz JR; Goswami D; Sharmeen AT; Rahman M; Lewis KDC; Rahman MZ; Barin B; Brooks WA; Neuzil KM
Clin Infect Dis; 2017 Nov; 65(11):1914-1920. PubMed ID: 29028980
[TBL] [Abstract][Full Text] [Related]
17. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
Mallory RM; Yi T; Ambrose CS
Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
[TBL] [Abstract][Full Text] [Related]
18. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49years.
Baxter R; Eaton A; Hansen J; Aukes L; Caspard H; Ambrose CS
Vaccine; 2017 Mar; 35(9):1254-1258. PubMed ID: 28162825
[TBL] [Abstract][Full Text] [Related]
19. The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults.
Ambrose CS; Wu X
Vaccine; 2013 Jan; 31(6):857-60. PubMed ID: 23261050
[TBL] [Abstract][Full Text] [Related]
20. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J;
Vaccine; 2015 Sep; 33(39):5110-7. PubMed ID: 26296497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
